

Generalized bullous drug eruption triggered by ceftriaxone: a case report and literature overview

Khuzama Alfalah,¹ Khalid Nabil Nagshabandi,² Hala Abdullah Almusa³

¹Division of Dermatology, Department of Internal Medicine and Critical Care, King Abdullah Bin Abdulaziz University Hospital, Riyadh; ²Department of Dermatology, College of Medicine, King Saud University, Riyadh; ³Department of Dermatology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia

Abstract

Ceftriaxone is a widely used third-generation cephalosporin antibiotic known for its efficacy and safety. However, hypersensitivity reactions, including rare cases of generalized bullous fixed drug eruption (GBFDE), have been reported. We present the case of a 68-year-old female with a history of multiple comorbidities who developed a generalized bullous drug eruption two days after initiating intravenous ceftriaxone for a suspected respiratory infection. Clinical evaluation revealed extensive bullae and ery-

thematous patches sparing mucous membranes, with histopathology confirming drug-induced epidermal changes. Direct immunofluorescence ruled out autoimmune bullous disorders. Prompt discontinuation of ceftriaxone, systemic corticosteroids, and supportive topical treatments led to marked clinical improvement. This case underscores the importance of recognizing rare but severe cutaneous reactions to ceftriaxone. Early diagnosis and intervention are crucial to minimizing complications and ensuring favorable outcomes.

Correspondence: Khalid Nabil Nagshabandi, Department of Dermatology, College of Medicine, King Saud University, PJ7C+89Q, 12372 Riyadh, Saudi Arabia.
E-mail: khaloed23@gmail.com
Tel.: +966 582940888

Key words: bullous drug eruption; ceftriaxone; cutaneous hypersensitivity; drug-induced bullous dermatoses; generalized bullous fixed drug eruption.

Conflict of interest: the authors declare no potential conflict of interest.

Ethics approval and consent to participate: ethics approval is not required for this study in accordance with local or national guidelines.

Consent for publication: written informed consent was obtained from the patient for publication of the details of her medical case and any accompanying images.

Availability of data and materials: all data generated or analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author.

Received: 2 December 2024.

Accepted: 14 February 2025.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

©Copyright: the Author(s), 2025

Licensee PAGEPress, Italy

Dermatology Reports 2025; 17:10208

doi:10.4081/dr.2025.10208

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Introduction

Ceftriaxone is a third-generation cephalosporin antibiotic widely used in clinical practice due to its broad-spectrum activity against various gram-positive and gram-negative bacteria. Administered primarily through parenteral routes, ceftriaxone is particularly effective for treating infections of the respiratory system, urinary tract, skin, soft tissues, and bloodstream, as well as bacterial meningitis. Its extended half-life allows for once-daily dosing, making it a convenient option for both inpatient and outpatient care.¹

Despite its efficacy and relatively low toxicity, ceftriaxone, like other antibiotics, is associated with adverse reactions, including hypersensitivity reactions. These reactions can manifest in various forms, with cutaneous drug eruptions being one of the most frequently encountered.^{2,3} Numerous reports have documented ceftriaxone-induced drug eruptions, including severe conditions such as drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), and toxic epidermal necrolysis (TEN).⁴⁻⁶ Bullous-like drug eruptions characterized by widespread blistering and detachment of the skin have also been documented.⁷ These severe drug reactions not only compromise the integrity of the skin but also pose significant clinical challenges due to their potential complications, requiring swift recognition and treatment. To date, only one prior case of ceftriaxone-induced generalized bullous fixed drug eruption (GBFDE) has been documented.⁷ Herein, we present a new case, adding to the growing literature on cephalosporin hypersensitivity reactions.

Case Report

A 68-year-old female, known to have a medical history of hypertension, diabetes mellitus, atrial fibrillation, and ischemic heart disease, presented to the emergency department with fever, worsening shortness of breath, and signs of fluid overload. She was admitted with an impression of decompensated heart failure and was started on intravenous furosemide. To manage a suspect-

ed respiratory infection, the patient was also started on intravenous ceftriaxone. Her home medications included apixaban 5 mg twice daily for atrial fibrillation, bisoprolol 5 mg, nifedipine 90 mg, and valsartan 160 mg. The patient had two previous hospital admissions, all of which were caused by volume overload signs and symptoms and managed with intravenous diuretics. She had no personal or family history of dermatologic conditions or any recent over-the-counter drug or substance use.

Two days after starting ceftriaxone, the patient developed a generalized skin rash. Physical examination showed widespread erythematous-violaceous to dusky patches and plaques of varying sizes, with overlying large, tense, fluid-filled bullae, with clear or slightly yellowish fluid, some of which have collapsed, leaving erosive or crusted areas. The plaques mainly involved the abdomen, back, upper, and lower extremities (Figures 1 and 2). Her palms, soles, and mucous membranes were not involved, and the Nikolsky sign was negative. Laboratory investigations showed

a normal neutrophil count. Based on the clinical presentation and the timing of drug administration, the impression of a bullous-like drug eruption and bullous pemphigoid, most likely caused by ceftriaxone, was maintained. Two 4 mm skin punch biopsies of the lesional and perilesional skin were obtained from the right thigh. Histopathological examination showed epidermal vacuolar alteration and bullous formation with dermal eosinophils, consistent with a drug-induced eruption (Figure 3). Direct immunofluorescence was negative for IgA, IgG, IgM, and C3, ruling out an autoimmune bullous disease. No evident full-thickness TEN was identified, and no evident infectious process was present. The overall morphological features were suggestive of early drug eruption epidermal changes associated with bullous formation rather than a pustular neutrophilic inflammation. Based on the clinical and histopathological characteristics, with the exclusion of other potential causes, a diagnosis of generalized bullous drug eruption, likely induced by ceftriaxone, was made.




Figure 1. The lesions are distributed bilaterally on the thighs and consist of well-demarcated erythematous plaques interspersed with multiple tense bullae of varying sizes. The bullae contain clear, yellowish fluid and are surrounded by erythematous halos.



Figure 2. Discrete erythematous macules and patches are scattered across the abdominal surface with minimal coalescence. The lesions lack vesiculation or bullae but show diffuse erythema. The arms also exhibit erythematous plaques with central ecchymosis and extensive purpuric discoloration, with active fluid-filled bullae visible.




Figure 3. A) Medium-power view of photomicrographs reveals epidermal early vacuolar alteration and bullous formation with underlying few dermal eosinophils; B) epidermal sloughing and blister formation with underlying dermal eosinophils (H&E stain, original magnification x20).

Table 1. Review summary of documented cases of ceftriaxone-induced generalized bullous drug eruption.

Case (year)	Age (years) /gender	Initiation of rash after commencing ceftriaxone	MM involvement	Histopathology	DIF	Management	Prognosis and outcome
Rathva <i>et al.</i> (2024)	66/female	1 day	Positive involvement	Not done	Not done	<p>Discontinuation of ceftriaxone</p> <p>Systemic therapy:</p> <ul style="list-style-type: none"> Prednisolone 5 mg orally, four doses administered with milk Levocetirizine 5 mg twice daily <p>Topical therapy:</p> <ul style="list-style-type: none"> Betamethasone cream for localized inflammation Fusidic acid cream for antibacterial coverage <p>Oral care:</p> <ul style="list-style-type: none"> Triamcinolone oral paste for local application Chlorhexidine gargles for antiseptic oral care 	Significant clinical improvement in the patient's condition was observed
Alfalah <i>et al.</i> (present case) (2024)	68/female	2 days	Not involved	Epidermal vacuolar alteration and bullous formation with dermal eosinophils	Negative for IgA, IgG, IgM, C3	<p>Discontinuation of ceftriaxone</p> <p>Systemic therapy:</p> <ul style="list-style-type: none"> Course of oral prednisolone 40 mg once daily initiated for five days to control the inflammatory response Omeprazole 40 mg for gastric protection <p>Topical therapy:</p> <ul style="list-style-type: none"> Topical clobetasol propionate 0.05% ointment to be applied twice daily to the affected areas Fusidic acid applied to any ruptured bullae 	Significant clinical improvement in the patient's condition was observed

MM, mucous membrane; DIF, direct immunofluorescence.

The management plan involved immediate discontinuation of ceftriaxone. The patient was prescribed topical clobetasol propionate 0.05% ointment to be applied twice daily to the affected areas, and fusidic acid was applied to any ruptured bullae. A course of oral prednisolone 40 mg once daily was initiated for five days to control the inflammatory response, along with omeprazole 40 mg for gastric protection. The patient was instructed to monitor for any signs of mucosal involvement or systemic symptoms and to contact the medical team if these developed. Within one week, there was a marked improvement in the rash, with the resolution of bullae. By the end of the second week, all lesions had healed completely, leaving only patches of post-inflammatory hyperpigmentation. No recurrence was observed at follow-up.

Discussion

GBFDE is a rare and severe type of fixed drug eruption (FDE) characterized by widespread blistering and erosive lesions at multiple anatomical sites. GBFDE usually appears as well-defined erythematous patches that can develop into bullae and can recur at the same location when the offending drug is used again.⁷ Within hours of injection, these lesions may appear and often resolve with some persistent hyperpigmentation. Notably, GBFDE's confined, recurrent nature and lower risk of complete skin detachment distinguish it from other reactions like TEN and Stevens-Johnson Syndrome.^{7,8} GBFDE is well-documented with medications such as antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and antiepileptics. Ceftriaxone, as reported in our case and similar ones, stands out among cephalosporins due to its ability to act as a hapten, eliciting an immune response. Other antibiotics like sulfamethoxazole-trimethoprim and fluoroquinolones have also been implicated.^{7,8} Despite its broad-spectrum effectiveness and safety, ceftriaxone is still associated with hypersensitivity reactions. T-cell-mediated responses are thought to play a role in the pathophysiology of GBFDE, where skin cell death and bullous development may result from T-cell reactivation at drug re-administration sites. The mechanism underlying GBFDE involves CD8⁺ memory T cells, which are reactivated upon re-exposure to the causative drug. These T cells release perforin and granzyme, leading to keratinocyte apoptosis and subsequent epidermal necrosis.^{8,9} Ceftriaxone, as a cephalosporin, may act as a hapten, altering self-antigens and eliciting an immune-mediated response. Histological features observed in this case – vacuolar interface changes and eosinophilic infiltration – are consistent with findings from drug-induced bullous dermatoses.^{7,10} These features confirm a hypersensitivity reaction rather than autoimmune blistering disorders like bullous pemphigoid.

Drug-associated bullous pemphigoid (DABP) is increasingly recognized in clinical practice. It mimics idiopathic BP in clinical, histological, and immunological presentations but is triggered by medications. The systematic review by Verheyden *et al.* identified 89 drugs implicated in DABP, with dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) being the most notable class.⁹ Gliptins, such as vildagliptin and linagliptin, have shown strong associations, particularly in elderly diabetic patients. The underlying mechanism involves DPP-4 inhibitors altering immune regulation, leading to autoantibody production against BP180 and BP230.^{9,10}

In our case, the patient developed extensive bullous lesions two days after commencing ceftriaxone for a suspected lung infection. The patient's histopathological results were consistent with those seen in ceftriaxone-induced GBFDE instances that had been

previously reported.⁷ Her lesions, however, were limited to the skin, protecting mucous membranes and preventing problems like secondary infections, in contrast to patients with mucosal involvement and notable systemic symptoms. Early intervention's effectiveness in reducing the severity of the eruption was demonstrated by the improvement that resulted from prompt identification and termination of ceftriaxone in conjunction with anti-inflammatory therapy. Previous reports, including the one by Rathva *et al.* (Table 1), emphasize the importance of being vigilant in vulnerable populations. Ceftriaxone-induced GBFDE can be particularly severe in patients with comorbidities, such as chronic kidney disease. Studies suggest that these comorbid conditions, especially impaired renal function, may enhance antigen presentation and hypersensitivity, increasing the risk of severe drug reactions.^{7,10}

Conclusions

Ceftriaxone-induced GBFDE is a rare and uncommon clinical presentation. Clinicians should promptly discontinue the suspected medication and conduct confirmatory histological investigations to distinguish GBFDE from more severe dermatoses. Early dermatological consultation, proper documentation of drug allergies, and patient education on hypersensitivity reactions are crucial for preventing recurrence.

References

- Richards DM, Heel RC, Brogden RN, et al. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use. *Drugs* 1984;27:469-527.
- Ozkaya E, Mirzoyeva L, Jhaish MS. Ceftriaxone-induced fixed drug eruption: first report. *Am J Clin Dermatol* 2008;9:345-7.
- Al-Ansari RY, Almuhaish LA, Hassan KA, et al. A Saudi Woman with Ceftriaxone Induced Fixed Drug Eruption. *Case Rep Dermatol Med* 2024;2024:9975455.
- Guleria VS, Dhillon M, Gill S, Naithani N. Ceftriaxone induced drug rash with eosinophilia and systemic symptoms. *J Res Pharm Pract* 2014;3:72-4.
- Shah MM, Dhanani S, Patel K, Nair P. Acute generalized exanthematous pustulosis following ceftriaxone. *Indian J Pharmacol* 2024;56:297-8.
- Lee JH, Ju IN, Cho HJ, et al. Toxic Epidermal Necrolysis by Ceftriaxone in Patient with Newly Diagnosed Systemic Lupus Erythematosus. *J Rheum Dis* 2013;20:374-7.
- Rathva T, Sinha A, Solanki V, Kanjariya D. A case of generalized bullous fixed drug eruptions induced by ceftriaxone. *Int J Basic Clin Pharmacol* 2024;13:726-8.
- Anderson HJ, Lee JB. A Review of Fixed Drug Eruption with a Special Focus on Generalized Bullous Fixed Drug Eruption. *Medicina (Kaunas)* 2021;57:925.
- Verheyden MJ, Bilgic A, Murrell DF. A Systematic Review of Drug-Induced Pemphigoid. *Acta Derm Venereol* 2020;100:adv00224.
- Liu SD, Chen WT, Chi CC. Association Between Medication Use and Bullous Pemphigoid: A Systematic Review and Meta-analysis. *JAMA Dermatol* 2020;156:891-900.